Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy
Department of Pediatrics
Medical Subject Headings
Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Female; Genotype; HIV Infections; HIV-1; Humans; Immunization; Male; Poxviridae; Sequence Analysis, DNA
Immunology and Infectious Disease | Pediatrics
In most human immunodeficiency virus type 1 (HIV-1)-infected individuals who achieve viral loads of /ml during highly active antiretroviral therapy (HAART), low levels of plasma virus remain detectable for years by ultrasensitive methods. The relative contributions of ongoing virus replication and virus production from HIV-1 reservoirs to persistent low-level viremia during HAART remain controversial. HIV-1 vaccination of HAART-treated individuals provides a model for examining low-level viremia, as immunizations may facilitate virus replication and sequence evolution. In a phase 1 trial of modified vaccinia virus Ankara/fowlpox virus-based HIV-1 vaccines in 20 HIV-infected young adults receiving HAART, we assessed the prevalence of low-level viremia and sequence evolution, using ultrasensitive viral load (
Shiu, Carlum; Cunningham, Coleen K.; Greenough, Thomas C.; Muresan, Petronella; Sanchez-Merino, Victor; Carey, Vincent J.; Jackson, J. Brooks; Ziemniak, Carrie; Fox, Lawrence; Belzer, Marvin; Ray, Stuart C.; Luzuriaga, Katherine; and Persaud, Deborah, "Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy" (2009). Immunology/Infectious Disease. 63.